CN1093126C - 合成被保护的(s)-3,4-二羟基丁酸酯的改进方法 - Google Patents

合成被保护的(s)-3,4-二羟基丁酸酯的改进方法 Download PDF

Info

Publication number
CN1093126C
CN1093126C CN97195996A CN97195996A CN1093126C CN 1093126 C CN1093126 C CN 1093126C CN 97195996 A CN97195996 A CN 97195996A CN 97195996 A CN97195996 A CN 97195996A CN 1093126 C CN1093126 C CN 1093126C
Authority
CN
China
Prior art keywords
acid
compound
formula
acid catalyst
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN97195996A
Other languages
English (en)
Chinese (zh)
Other versions
CN1223647A (zh
Inventor
T·E·扎克斯
D·E·布特勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of CN1223647A publication Critical patent/CN1223647A/zh
Application granted granted Critical
Publication of CN1093126C publication Critical patent/CN1093126C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/03Preparation of carboxylic acid esters by reacting an ester group with a hydroxy group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/30Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
CN97195996A 1996-07-29 1997-07-01 合成被保护的(s)-3,4-二羟基丁酸酯的改进方法 Expired - Fee Related CN1093126C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2236996P 1996-07-29 1996-07-29
US60/022,369 1996-07-29

Publications (2)

Publication Number Publication Date
CN1223647A CN1223647A (zh) 1999-07-21
CN1093126C true CN1093126C (zh) 2002-10-23

Family

ID=21809241

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97195996A Expired - Fee Related CN1093126C (zh) 1996-07-29 1997-07-01 合成被保护的(s)-3,4-二羟基丁酸酯的改进方法

Country Status (17)

Country Link
US (1) US5998633A (enExample)
EP (1) EP0915866B1 (enExample)
JP (1) JP2000515882A (enExample)
KR (1) KR100447370B1 (enExample)
CN (1) CN1093126C (enExample)
AT (1) ATE215078T1 (enExample)
AU (1) AU3515497A (enExample)
CO (1) CO4950542A1 (enExample)
DE (1) DE69711391T2 (enExample)
DK (1) DK0915866T3 (enExample)
ES (1) ES2176756T3 (enExample)
HU (1) HU226465B1 (enExample)
IL (1) IL127058A (enExample)
PT (1) PT915866E (enExample)
TR (1) TR199900191T2 (enExample)
WO (1) WO1998004543A1 (enExample)
ZA (1) ZA976705B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2176756T3 (es) * 1996-07-29 2002-12-01 Warner Lambert Co Proceso perfeccionado para la sintesis de los esteres protegidos del acido (s)-3,4-dihidroxibutirico.
KR100332703B1 (ko) * 1998-07-24 2002-08-27 삼성정밀화학 주식회사 광학활성을갖는(s)-3,4-에폭시부티르산염의제조방법
US6713290B2 (en) 1998-07-24 2004-03-30 Samsung Fine Chemicals Co., Ltd. Process for preparing optically pure (S)-3-hydroxy-γ-butyrolactone
JP3364482B2 (ja) * 1998-07-24 2003-01-08 サムスン ファイン ケミカルズ カンパニー リミテッド 光学的に純粋な(S)−3−ヒドロキシ−γ−ブチロラクトンの連続的な製造方法
US6235930B1 (en) * 1999-03-31 2001-05-22 Board Of Trustees Operating Michigan State University Process for the preparation of 3,4-dihydroxybutanoic acid and derivatives thereof from substituted pentose sugars
HU227840B1 (en) * 1999-05-06 2012-05-02 Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag Intermediates of atorvastatin synthesis and process for producing them
ES2252088T3 (es) 1999-12-17 2006-05-16 Pfizer Science And Technology Ireland Limited Procedimiento de produccion a escala industrial de la hemisal de calcio de la atorvastatina trihidrato cristalina.
ES2258030T3 (es) * 1999-12-17 2006-08-16 Pfizer Science And Technology Ireland Limited Procedimiento para producir atorvastatina calcio cristalina.
JP4598917B2 (ja) * 2000-04-28 2010-12-15 ダイセル化学工業株式会社 ラクトンの製造方法
KR100645665B1 (ko) 2000-07-27 2006-11-13 에스케이 주식회사 (s)-베타-하이드록시-감마-부티로락톤의 연속 제조방법
EP1728785A1 (en) 2001-01-09 2006-12-06 Warner-Lambert Company LLC 7-[(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-heptanoic acid ester 3,5-dioxo-acetal
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
IL158790A0 (en) 2001-06-29 2004-05-12 Warner Lambert Co Crystalline forms of [r-(*,r*)]-2-(4-fluorophenyl) -beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
CA2451159A1 (en) * 2001-07-06 2003-01-16 Teva Pharmaceutical Industries Ltd. Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives
CA2475586C (en) * 2002-02-25 2011-07-05 Biocon Limited Novel boronate esters
GB0211716D0 (en) 2002-05-22 2002-07-03 Phoenix Chemicals Ltd Process
ES2287549T3 (es) 2002-08-06 2007-12-16 Warner-Lambert Company Llc Procedimiento para preparar la fenilamida del acido 5-(4-fluorofenil)-1-(2-((2r,4r)-4-hidroxi-6-oxo-tetrahidropiran-2-il)etil)-2-isopropil-4-fenil-1h-pirrol-3-carboxilico.
JP2005539078A (ja) * 2002-09-18 2005-12-22 エス ケー コーポレイション 光学的に純粋な(S)−β−ヒドロキシ−γ−ブチロラクトンの連続製造方法
EP1625223A4 (en) * 2002-09-20 2009-11-11 Verenium Corp CHEMOENZYMATIC PROCEDURES FOR SYNTHESIS OF STATINES AND STATIN INTERCONNECTIONS
US6713639B1 (en) 2002-10-28 2004-03-30 Council Of Scientific And Industrial Research Process for preparing enantiomerically pure (S)-3-hydroxy-gamma-butyrolactone
US20060205804A1 (en) * 2003-04-14 2006-09-14 Nelson James D Process for preparing 5-(4-fluorophenyl)-1-[2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl) ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
ATE425132T1 (de) * 2003-04-22 2009-03-15 Biocon Ltd Neues verfahren zur stereoselektiven reduktion von beta-ketoestern
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
MXPA06003003A (es) * 2003-09-17 2006-06-23 Warner Lambert Co Formas cristalinas de acido [r-(r*, r*)]-2-(4- fluorofenil)-(, (-dihidroxi -5-(1- metiletil)-3 -fenil-4 -[(fenilamino) -carbonil]- 1h-pirrol -1-heptanoico.
WO2005068642A2 (en) 2003-10-01 2005-07-28 Board Of Trustees Operating Michigan State University Bacterial synthesis of 1,2,4-butanetriol enantiomers
AU2005232959A1 (en) * 2004-04-16 2005-10-27 Pfizer Products Inc. Process for forming amorphous atorvastatin calcium
EP3581564A1 (en) 2004-05-05 2019-12-18 Pfizer Products Inc. Diethylamine salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
CA2573771C (en) 2004-07-20 2011-05-10 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .gamma.-dihydroxy-5-(1-menthylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
AU2005298383A1 (en) 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
CA2589537A1 (en) * 2004-12-02 2006-06-08 Stephen Craig Dyar Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
DE602006013815D1 (de) * 2005-05-31 2010-06-02 Kowa Co Verfahren zur herstellung von optisch aktiven ppar-aktivierenden verbindungen und zwischenprodukte für die herstellung
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
ES2304335T3 (es) 2005-11-21 2010-05-19 Warner-Lambert Company Llc Formas nuevas del acido (r-(r*,r*))-2-(4-fluorofenil)-b,b-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)1h-pirrol-1-heptanoico, de magnesio.
US20110165641A1 (en) * 2006-03-31 2011-07-07 The Board Of Trustees Of Michigan State University Synthesis of 1,2,4-Butanetriol Enantiomers from Carbohydrates
BRPI0714439A2 (pt) * 2006-07-19 2014-04-08 Univ Michigan State Processos para a preparação de d-1,2,4-butanotriol de trinitrato de 1,2,4-butanotriol, de ácido d-3,4-diidroxibutanóico, de ácido 3-desoxi-d-gliceropentanóico, de ácido (4s)-2-amino-4,5-diidroxipentanóico; d-1,2,4-butanotriol trinitrato de d-1,2,4-butanotriol, d-xilose desidrogenase, ácido d-xilônico, desidratase, ácido 3-desoxi-gliceropentanóico, ácido d-3-4-diidroxibutanóico, ácido (4s)-2-amino-4,5-diidroxipentanóico; ácidos nucléicos codificadores de uma d-xilose ou recombinantes, para biossíntese de 1,2,4-butanotriol, do ácido (4s)-2-amino-4,5-diidroxipentanóico, do ácido d-3-4-diidroxibutanóico, do ácido (4s)-2-amino-4,5-diidroxipentanóico; vetor knock-out de uma 3-desoxi-d-glicero-pentulossonato aldolase, entidade celular recombinante, célula recombinate, processo para investigação de polinucleotídeos candidatos codificadores de enzimas, anticorpo.
KR100850558B1 (ko) 2008-01-02 2008-08-06 조동옥 아토르바스타틴의 효율적인 제조방법
JP2009256316A (ja) 2008-03-28 2009-11-05 Daicel Chem Ind Ltd β−ヒドロキシ−γ−ブチロラクトンの製造方法
CN101337906B (zh) * 2008-08-15 2012-06-27 河南豫辰精细化工有限公司 一种4-甲基-3-氧代-n-苯基戊酰胺的制备方法
WO2010069593A1 (en) 2008-12-19 2010-06-24 Krka, D. D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
MX2013015272A (es) 2011-07-01 2014-04-14 Dsm Sinochem Pharm Nl Bv Cristales micronizados.
CN106397241A (zh) * 2016-08-23 2017-02-15 杨锋 一种4‑甲基‑3‑氧代‑n‑苯基戊酰胺的绿色环保后处理方法
CN106588689A (zh) * 2016-12-15 2017-04-26 河南豫辰药业股份有限公司 一种从结晶母液废液中回收阿托伐他汀中间体m4的方法
CN112939901B (zh) * 2021-02-09 2023-05-09 中国科学院福建物质结构研究所 一种α-羟基-γ-丁内酯的制备方法
CN114195670B (zh) * 2021-12-31 2024-03-15 河南豫辰药业股份有限公司 一种阿托伐他汀母核m4的精制方法
CN117447350A (zh) * 2023-10-26 2024-01-26 河南豫辰药业股份有限公司 一种阿托伐他汀m4有机废物综合再利用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292939A (en) * 1991-05-13 1994-03-08 Board Of Trustees Operating Michigan State University Process for the preparation of 3,4-dihydroxybutanoic acid and salts thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2710688B2 (ja) * 1990-10-09 1998-02-10 鐘淵化学工業株式会社 4―ブロモ―3―ヒドロキシ酪酸エステル誘導体の製造法
JP3351563B2 (ja) * 1992-12-03 2002-11-25 鐘淵化学工業株式会社 3−ヒドロキシ酪酸誘導体の製造法
ES2176756T3 (es) * 1996-07-29 2002-12-01 Warner Lambert Co Proceso perfeccionado para la sintesis de los esteres protegidos del acido (s)-3,4-dihidroxibutirico.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292939A (en) * 1991-05-13 1994-03-08 Board Of Trustees Operating Michigan State University Process for the preparation of 3,4-dihydroxybutanoic acid and salts thereof

Also Published As

Publication number Publication date
TR199900191T2 (xx) 1999-04-21
CO4950542A1 (es) 2000-09-01
JP2000515882A (ja) 2000-11-28
ES2176756T3 (es) 2002-12-01
DE69711391D1 (de) 2002-05-02
ZA976705B (en) 1998-02-10
HUP9904348A2 (hu) 2000-04-28
IL127058A (en) 2001-07-24
AU3515497A (en) 1998-02-20
PT915866E (pt) 2002-07-31
KR100447370B1 (ko) 2004-09-08
DK0915866T3 (da) 2002-06-10
EP0915866A1 (en) 1999-05-19
HUP9904348A3 (en) 2004-03-01
EP0915866B1 (en) 2002-03-27
HK1020728A1 (en) 2000-05-19
US5998633A (en) 1999-12-07
DE69711391T2 (de) 2002-11-07
IL127058A0 (en) 1999-09-22
WO1998004543A1 (en) 1998-02-05
ATE215078T1 (de) 2002-04-15
HU226465B1 (en) 2008-12-29
CN1223647A (zh) 1999-07-21
KR20000029648A (ko) 2000-05-25

Similar Documents

Publication Publication Date Title
CN1093126C (zh) 合成被保护的(s)-3,4-二羟基丁酸酯的改进方法
JP3429500B2 (ja) 4−シアノ−3−ヒドロキシ酪酸エステルの製造方法
EP1077212B1 (en) Process for producing 6-cyanomethyl-1,3-dioxane-4-acetic acid derivatives
CN1122029C (zh) 制备辛伐他汀的方法
JP3822644B2 (ja) 1,3―ジオキソラン―4―メタノール化合物の製造法
JPH04211075A (ja) アルキレンカーボネートの製造法
JPWO1998011087A1 (ja) 1,3−ジオキソラン−4−メタノール化合物の製造法
WO2003018570A1 (en) Process of lactonization in the preparation of statins
US20130197243A1 (en) Salts of 7-amino-3,5-dihydroxyheptanoic acid esters
WO2008075165A1 (en) Novel process for the synthesis of [r-(r*, r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid or a pharmaceutically acceptable salt thereof
EP0943612B1 (en) Process for producing cyclic carbonic esters
JP3076154B2 (ja) (3r,5s)−3,5,6−トリヒドロキシヘキサン酸誘導体及びその製造方法
CN1332736A (zh) 合成5-(α-羟基烷基)苯并[1,3]二氧杂环戊烯的方法
JP3303327B2 (ja) 不斉誘起触媒
JPS62289549A (ja) N−(α−アルコキシエチル)−カルボン酸アミドの製造方法
HK1020728B (en) Improved process for the synthesis of protected esters of (s)-3,4-dihydroxybutyric acid
EP1167365B1 (en) Method of producing sesamol formic acid ester and sesamol
RU2214407C2 (ru) Усовершенствованный способ лактонизации при получении статинов
CN1202102C (zh) 2-香豆酮和取代的2-香豆酮的生产方法
JP4598917B2 (ja) ラクトンの製造方法
KR920000953B1 (ko) 광학활성 3, 4-디히드록시 부티르산 유도체의 제조방법
JP3900202B2 (ja) 1,3−ジオキソラン−4−メタノール化合物の製造法
JPH06102636B2 (ja) N―メチル―3,4―ジメトキシフェニルエチルアミンの新規合成方法
CN1732149A (zh) 合成3,3A,6,6A-四氢-2H-环戊烯并[b]呋喃-2-酮的方法
JPH0769960A (ja) 光学活性2−ノルボルナノンの製造方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Assignee: Pfizer Pharmaceuticals Limited

Assignor: Vonil Longbow (Warner & Lambert) Pfizer, Inc.

Contract fulfillment period: Contract performance period from January 10, 2006 to January 10, 2009

Contract record no.: Contract filing No. 061000010077

Denomination of invention: Improved methods for the synthesis of protected (S) -3, 4-, two butyric acid esters

Granted publication date: 20021023

Record date: 20060818

LIC Patent licence contract for exploitation submitted for record

Free format text: LICENCE; TIME LIMIT OF IMPLEMENTING CONTACT: 2006.1.10 TO 2009.1.10

Name of requester: PFIZER(WARNER-LAMBERT) PHARMACEUTICAL CO., LTD.

Effective date: 20060818

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20021023